ClinicalTrials.gg
Not yet recruitingNCT06841185Updated Feb 24, 2025

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

A Phase 3 interventional study of HLX13 and US-sourced YERVOY® in Hepatocellular Carcinoma (HCC), sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
656
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Read the detailed description

This study includes three treatment groups. Patients will be randomly assigned at a 2:1:1 ratio to the HLX13, US-sourced YERVOY®, or EU-sourced YERVOY® group to receive the treatment of IMPs in combination with nivolumab.

Patients with good tolerability and disease control will receive HLX13 or YERVOY® in combination with nivolumab on the first day of every 3 weeks for up to 4 cycles. PK and immunogenicity blood sampling will be conducted during the treatment period. After the four treatment cycles, all subjects will be subsequently treated with nivolumab monotherapy until investigator-assessed disease progression, initiation of a new anti-neoplastic therapy, withdrawal of informed consent, death, unacceptable toxicity, or up to 1 year after randomization, whichever occurs first.

02

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • Ipilimumab Biosimilar
03

In context

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

This study's planned enrollment of 656 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically diagnosed or advanced hepatocellular carcinoma not eligible for surgical or locoregional therapies according to the diagnostic criteria of the American Association for the Study of Liver Diseases (AASLD).
  • At least one as assessed by IRRC based on v1.1 within 4 weeks prior to the first dose in this study.
  • No systemic therapy for relapsed metastatic or advanced hepatocellular carcinoma prior to screening.
  • (ECOG) performance status (PS) 0 or 1.
  • Class A.
  • Normal major organ functions.
  • Women of should use highly effective methods of during the study and within 5 months after the last study treatment; Male subjects capable of fathering a child must agree to use at least one highly effective method of contraception for the duration of the study and for at least 7 months after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  • With other histopathological types of hepatocellular carcinoma.
  • History of hepatic encephalopathy.
  • ascites.
  • Patients with tumor thrombus at the main portal vein, left or right portal (either or both) vein branch, or inferior vena cava.
  • Presence of the central nervous system disorders at screening, except subjects who have previously received treatment for can participate in the study treatment if their clinical symptoms have been stable for at least 4 weeks.
  • Evidence of portal hypertension with bleeding esophageal or gastric varices within 6 months prior to the randomization.
  • Known active or suspected diseases.
  • Active co-infection with both and C, or hepatitis D infection in subjects with hepatitis B.
  • Uncontrolled cardiovascular diseases within 6 months.
  • Known interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe lung function abnormalities that may impede the investigators' diagnosis and management of drug-related pulmonary toxicity prior to screening.
  • Patients who have received any T-cell costimulatory agents or immune checkpoint blockade therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 () inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other agents that target T cells.
  • Patients who have other conditions not suitable for inclusion per investigator's judgments.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
656 participants (estimated)

Study arms

  • Experimental
    HLX13 group

    Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.

    Drug: HLX13

  • Active comparator
    US-sourced YERVOY® group

    US-sourced ipilimumab

    Drug: US-sourced YERVOY®

  • Active comparator
    EU-sourced YERVOY® group

    EU-sourced ipilimumab

    Drug: EU-sourced YERVOY®

Interventions

  • DrugHLX13

    HLX13 (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles

  • US-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles

  • EU-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  2. Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  3. Best Objective Response Rate (ORR) up to Week 24 (assessed by Independent Radiology Review Committee [IRRC] based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 24

Secondary outcomes

  1. Maximum serum drug concentration (Cmax) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  2. Trough serum drug concentration (Ctrough) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  3. Time to reach maximum serum drug concentration (Tmax) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  4. Elimination half-life (t1/2) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  5. Total clearance (CL) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  6. Volume of distribution during terminal phase (Vz) after the first dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 21

  7. Time to reach maximum serum drug concentration at steady state (Tmax, ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  8. Maximum serum drug concentration at steady state (Cmax, ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  9. Minimum serum drug concentration at steady state (Cmin, ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  10. Elimination half-life (t1/2) at steady state

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  11. Volume of distribution at steady state (Vss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  12. Total clearance at steady state (CLss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  13. Accumulation ratio of AUC (Rac, AUC)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  14. Accumulation ratio of Cmax (Rac, Cmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 85

  15. ORR assessed by IRRC (based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 30

  16. ORR assessed by investigators (based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  17. Duration of Response (DOR) assessed by investigators (based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  18. Time to Response (TTR) assessed by investigators (based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  19. Progression-Free Survival (PFS) Status assessed by investigators (based on RECIST v1.1)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  20. Progression-Free Survival Rate (PFSR) assessed by investigators (based on RECIST v1.1) at Weeks 24 and 48

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  21. Overall Survival (OS)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to 1 year

  22. Overall Survival Rate (OSR) assessed by investigators (based on RECIST v1.1) at Weeks 24 and 48

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Week 48

  23. Adverse events (AEs)

    Time frame: Up to Month 15

  24. Serious adverse events (SAEs)

    Time frame: Up to Month 15

  25. Incidence of anti-drug antibodies (ADAs).

    Time frame: Up to 1 year

  26. Incidence of neutralizing antibodies (NAbs).

    Time frame: Up to 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Jun 2027, 25 months later.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 25 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 24, 2025
StartEst.
Apr 30, 2025
Primary completionEst.
Jun 6, 2027
CompletionEst.
May 5, 2028
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841185
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Apr 30, 2025 (estimated)
Primary completion
Jun 6, 2027 (estimated)
Completion
May 5, 2028 (estimated)
Last update
Feb 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX13

Start the discussion